World Lupus Day
Lupus is a chronic, autoimmune disease that can damage any part of the body (skin, joints, and/or organs inside the body). Chronic means that the signs and symptoms tend to last longer than six weeks and often for many years.
In lupus, something goes wrong with your immune system, which is the part of the body that fights off viruses, bacteria, and germs ("foreign invaders," like the flu). Normally our immune system produces proteins called antibodies that protect the body from these invaders. Autoimmune means your immune system cannot tell the difference between these foreign invaders and your body’s healthy tissues ("auto" means "self") and creates autoantibodies that attack and destroy healthy tissue. These autoantibodies cause inflammation, pain, and damage in various parts of the body.
World Lupus Day is sponsored by the World Lupus Federation, a coalition of lupus patient organizations from around the world, united to improve the quality of life for people affected by lupus. Through coordinated efforts of its global affiliates, the World Lupus Federation works to create greater awareness and understanding of lupus, provide education and services to people living with the disease, and advocate on their behalf.
World Lupus Day serves to call attention to the impact that lupus has on people around the world. The annual observance focuses on the need for improved patient healthcare services, increased research into the causes of and cure for lupus, earlier diagnosis and treatment of lupus, and better epidemiological data on lupus globally. World Lupus Day serves to rally lupus organizations and people affected by the disease around the world for a common purpose of bringing greater attention and resources to efforts to end the suffering caused by this disabling and potentially fatal autoimmune disease.
Lupus is a Global Health Issue
Every day, more than 5 million people worldwide struggle with the often-debilitating health consequences of lupus, a potentially fatal autoimmune disease capable of damaging virtually any part of the body, including the skin, heart, lungs, kidneys, and brain. Lupus affects people in all parts of the world. While some groups of people develop lupus more frequently than others, lupus develops in people of all ages, races, ethnicities and genders.
Related news and insights
AbbVie announced topline results from a Phase II study of upadacitinib (Rinvoq, 30 mg) given alone or as combination therapy (ABBV-599) with a Bruton's Tyrosine Kinase inhibitor (elsubrutinib, 60 mg), once daily in patients with moderately to severely active systemic lupus erythematosus (SLE)
AstraZeneca’s Saphnelo (anifrolumab) has been approved in the European Union as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite receiving standard therapy.
Eli Lilly and Company and Incyte announced updates on the Phase III development program for Olumiant (baricitinib) in adults with active systemic lupus erythematosus (also referred to as SLE and lupus) and the status of the U.S. atopic dermatitis supplemental new drug application (sNDA).